G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 210-217

  Yamada, Takeshi ^a   Park, Chun Shik ^a   Shen, Ye ^a   Rabin, Karen R ^a   Lacorazza, H Daniel ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

G0S2; K562; Nucleolin; Proliferation

Indexed keywords

AZACITIDINE; NUCLEOLIN; SHORT HAIRPIN RNA; CELL CYCLE PROTEIN; G0S2 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN BINDING; RNA BINDING PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN K562; CONTROLLED STUDY; CYTOSOL; DEMETHYLATION; G0S2 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL LINE; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; HL 60 CELL LINE; K562 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CYTOSOL; GENES, TUMOR SUPPRESSOR; HL-60 CELLS; HUMANS; K562 CELLS; MICE; MICE, NUDE; PHOSPHOPROTEINS; PROTEIN BINDING; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84892515213     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.006     Document Type: Article

References (30)

1. Baylin S.B. DNA methylation and gene silencing in cancer. Nature Clin Pract Oncol 2005, 2(Suppl. 1):S4-S11.
2. Russell L., Forsdyke D.R. A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol 1991, 10:581-591.
3. Heckmann B.L., Zhang X., Xie X., Liu J. The G0/G1 switch gene 2 (G0S2): regulating metabolism and beyond. Biochim Biophys Acta 2013, 1831:276-281.
4. Yang X., Lu X., Lombes M., Rha G.B., Chi Y.I., Guerin T.M., et al. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab 2010, 11:194-205.
5. Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 2005, 392:313-324.
6. Kitareewan S., Blumen S., Sekula D., Bissonnette R.P., Lamph W.W., Cui Q., et al. G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 2008, 33:397-404.
7. Cristillo A.D., Heximer S.P., Russell L., Forsdyke D.R. Cyclosporin A inhibits early mRNA expression of G0/G1 switch gene 2 (G0S2) in cultured human blood mononuclear cells. DNA Cell Biol 1997, 16:1449-1458.
8. Welch C., Santra M.K., El-Assaad W., Zhu X., Huber W.E., Keys R.A., et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res 2009, 69:6782-6789.
9. Yamada T., Park C.S., Burns A., Nakada D., Lacorazza H.D. The cytosolic protein G0S2 maintains quiescence in hematopoietic stem cells. PLoS ONE 2012, 7:e38280.
10. Kusakabe M., Watanabe K., Emoto N., Aki N., Kage H., Nagase T., et al. Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists. Biochem Biophys Res Commun 2009, 390:1283-1287.
11. Tokumaru Y., Yamashita K., Osada M., Nomoto S., Sun D.I., Xiao Y., et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004, 64:5982-5987.
12. Zheng C., Li L., Haak M., Brors B., Frank O., Giehl M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia: Off J Leukemia Soc Am (Leukemia Research Fund, UK) 2006, 20:1028-1034.
13. Faber K., Bullinger L., Ragu C., Garding A., Mertens D., Miller C., et al. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARgamma signaling. J Clin Invest 2013, 123:299-314.
14. Crews L.A., Jamieson C.H. Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett 2013, 338:15-22.
15. Crews L.A., Jamieson C.H. Chronic myeloid leukemia stem cell biology. Curr Hematol Malign Rep 2012, 7:125-132.
16. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998, 92:3780-3792.
17. Li L.C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431.
18. Diaz-Blanco E., Bruns I., Neumann F., Fischer J.C., Graef T., Rosskopf M., et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia: Off J Leukemia Soc Am (Leukemia Research Fund, UK) 2007, 21:494-504.
19. Schutte B.C., Bjork B.C., Coppage K.B., Malik M.I., Gregory S.G., Scott D.J., et al. A preliminary gene map for the Van der Woude syndrome critical region derived from 900kb of genomic sequence at 1q32-q41. Genome Res 2000, 10:81-94.
20. Jin B., Li Y., Robertson K.D. DNA methylation: superior or subordinate in the epigenetic hierarchy?. Genes Cancer 2011, 2:607-617.
21. Oh B., Kim T.Y., Min H.J., Kim M., Kang M.S., Huh J.Y., et al. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells. Anticancer Drugs 2013, 24:20-31.
22. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012, 13:679-692.
23. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
24. Westbrook C.A., Rubin C.M., Carrino J.J., Le Beau M.M., Bernards A., Rowley J.D. Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis. Blood 1988, 71:697-702.
25. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
26. Jelinek J., Gharibyan V., Estecio M.R., Kondo K., He R., Chung W., et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS ONE 2011, 6:e22110.
27. Kusakabe M., Kutomi T., Watanabe K., Emoto N., Aki N., Kage H., et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. Int J Cancer 2010, 126:1895-1902.
28. Mongelard F., Bouvet P. Nucleolin: a multiFACeTed protein. Trends Cell Biol 2007, 17:80-86.
29. Otake Y., Soundararajan S., Sengupta T.K., Kio E.A., Smith J.C., Pineda-Roman M., et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood 2007, 109:3069-3075.
30. Ishimaru D., Zuraw L., Ramalingam S., Sengupta T.K., Bandyopadhyay S., Reuben A., et al. Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1). J Biol Chem 2010, 285:27182-27191.